.png)
WEB予約
LINE予約
WEB予約
LINE予約
STD
Pharyngeal gonorrhea (gonococcal infection of the throat) is a sexually transmitted infection in which Neisseria gonorrhoeae colonizes the pharyngeal mucosa through oral sex, and 80-90% of affected men remain asymptomatic – a true “silent infection.” Most patients experience only mild throat discomfort or postnasal phlegm resembling a common cold, but if left untreated they become unwitting carriers who reseed genital infection in their partners, and the pharynx is a recognized reservoir for the emergence of antimicrobial-resistant gonorrhea – a global concern flagged by the WHO. In this article, the physicians of Men’s Care Clinic provide a thorough, male-focused review of pharyngeal gonorrhea – transmission routes, symptom patterns, accurate diagnosis by gargle PCR, ceftriaxone 1 g single-dose intramuscular therapy, and the importance of test of cure.
Table of Contents
“My throat discomfort just won’t go away,” “Cold medicine isn’t helping,” “My throat felt strange after receiving oral sex” – behind such complaints, pharyngeal gonorrhea (gonococcal infection of the throat) may be hiding. While Neisseria gonorrhoeae is best known as a cause of urethritis, the rise of oral sex has produced a major increase in pharyngeal gonococcal infections, and this site has become a clinically important diagnosis in male STD practice.
The bottom line: pharyngeal gonorrhea is a “triple-threat” infection – hard to notice, hard to treat, and prone to resistance. In men, 80-90% of cases are asymptomatic, meaning carriers feel essentially nothing despite being infected. In addition, antibiotic delivery to the pharyngeal mucosa is lower than at the urethra, so treatment failure and relapse occur more often. The WHO classifies N. gonorrhoeae as a “priority pathogen” and has warned against the accelerating emergence of antimicrobial resistance.
If left untreated, the throat acts as a reservoir that re-seeds genital infection in partners, and although rare, disseminated gonococcal infection (DGI: arthritis, skin lesions, sepsis) has been reported. Below, the physicians of Men’s Care Clinic – who diagnose and treat many cases of pharyngeal gonorrhea in our STD clinic – provide a structured, practical guide so that men can identify, test for, treat, and prevent recurrence of pharyngeal gonorrhea.
Pharyngeal gonorrhea refers to colonization of the pharyngeal mucosa (pharynx, tonsils, base of the tongue) by Neisseria gonorrhoeae. The gonococcus has high affinity for mucosal surfaces such as the urethra, endocervix, and rectum, but the global popularity of oral sex has driven a worldwide rise in pharyngeal cases. In Japan, surveillance data from 2023 reported approximately 9,000 cases of gonococcal infection, and pharyngeal gonorrhea is estimated to account for 5-30% of male cases – even higher among MSM (men who have sex with men).
The “STI Diagnosis and Treatment Guidelines 2020” jointly issued by Japan’s Ministry of Health, Labour and Welfare and the Japanese Society for Sexually Transmitted Infections lists pharyngeal gonorrhea as an independent clinical category alongside urethral and endocervical gonorrhea, with standardized diagnostic and treatment recommendations. Because men more often lack symptoms and harbor relatively high pharyngeal carriage, they are epidemiologically recognized as a “silent reservoir.”
The defining feature of pharyngeal gonorrhea is prolonged, asymptomatic carriage that continually re-seeds sexual partners. Moreover, the pharynx hosts a rich resident microbiota with which N. gonorrhoeae can exchange genetic material – creating a particularly high risk of multidrug-resistant (AMR) evolution – a worldwide public-health priority.
| Item | Pharyngeal gonorrhea | Urethral gonorrhea |
|---|---|---|
| Infection site | Pharynx, tonsils, base of tongue | Anterior urethra, corpus spongiosum |
| Main transmission | Oral sex, deep kissing | Vaginal intercourse, anal sex |
| Symptomatic rate (men) | 10-20% (asymptomatic 80-90%) | 80-90% (asymptomatic 10-20%) |
| Typical symptoms | Throat discomfort, phlegm, low-grade fever | Painful urination, yellow-white purulent discharge |
| Incubation | 2-7 days | 2-7 days |
| Test specimen | Gargle wash, pharyngeal swab | First-void urine, urethral discharge |
| Treatment difficulty | Difficult (low drug penetration) | Straightforward (high cure rates) |
| Test of cure | Mandatory (2-4 weeks after treatment) | Only if symptoms recur |
As shown above, pharyngeal gonorrhea is markedly more difficult to test and treat than urethral disease, and a follow-up test of cure is standard.
The defining feature of pharyngeal gonorrhea is that 80-90% of men remain asymptomatic throughout the course of infection. This stands in stark contrast to urethral gonorrhea, which usually produces strong symptoms (painful urination, purulent discharge), because the gonococcus typically elicits only minimal local inflammation in the pharyngeal mucosa. The risk of silent transmission to sexual partners is therefore extremely high.
Even when symptoms occur, they tend to be mild and difficult to distinguish from the common cold or routine tonsillitis. Patients may experience nothing more than a mild scratchy throat or postnasal drip for a few days to weeks before spontaneous improvement, and both patients and clinicians can easily overlook gonococcal infection as a cause.
These features closely resemble bacterial pharyngitis, tonsillitis, or streptococcal infection, so without a deliberate gonococcal test the diagnosis is often missed. Any man with a history of oral sex should request a dedicated STD-clinic PCR test.
| Condition | Main symptoms | Fever | Pain severity | Distinguishing clues |
|---|---|---|---|---|
| Pharyngeal gonorrhea | Discomfort, phlegm, mild fever | Mild | Weak | Sexual contact history; many asymptomatic |
| Pharyngeal chlamydia | Discomfort, mild sore throat | None to mild | Weak | Even higher asymptomatic rate than gonorrhea |
| Streptococcal pharyngitis | Severe sore throat, painful swallowing | High | Strong | May have strawberry tongue or rash |
| Viral pharyngitis | Sore throat, runny nose, cough | Mild to moderate | Moderate | Accompanied by general cold symptoms |
| Acute tonsillitis | Severe sore throat, white exudate | High | Strong | Marked tonsillar swelling with pus plugs |
If mild symptoms persist for a long time, or symptoms improved with antibiotics but came back weeks later, pharyngeal gonorrhea or chlamydia must be considered.
Asymptomatic pharyngeal gonorrhea functions as a hidden reservoir that re-seeds N. gonorrhoeae through a sexual network. Because carriers feel healthy, they do not take preventive measures and unknowingly transmit infection to the urethra, endocervix, or rectum of partners, who then pass it to the pharynx of additional partners. The notion that no symptoms equals no problem does not apply to pharyngeal gonorrhea; periodic screening based on sexual history is the single most effective prevention strategy.
The principal route of pharyngeal gonorrhea is transfer of N. gonorrhoeae from the genital or rectal mucosa to the oral and pharyngeal mucosa. The main practices are oral sex (fellatio or cunnilingus), deep kissing, and oral-anal contact (rimming). Condomless oral sex is the single largest risk factor for pharyngeal gonorrhea.
The notion that oral sex is safe is a misconception: gonorrhea, chlamydia, syphilis, HPV, herpes, and many other STIs are readily transmitted via the oropharyngeal route. The fact that men can acquire pharyngeal gonorrhea even from cunnilingus (performing oral sex on a female partner) is often overlooked.
| Activity | Risk level | Notes |
|---|---|---|
| Fellatio (receiving partner penis in mouth) | Very high | Direct exposure of the throat to gonococci on the penis |
| Cunnilingus (male performing oral sex on female) | Moderate to high | Possible if the female partner has endocervical gonorrhea |
| Rimming / oral-anal contact | Moderate to high | From a partner with rectal gonorrhea |
| Deep kissing (pharynx to pharynx) | Moderate | Moderate risk when both have pharyngeal carriage |
| Ordinary kissing (lips only) | Low | Low risk, but not zero |
| Shared utensils / towels | Negligible | Gonococci die rapidly outside the body, essentially zero risk |
In short, any sexual practice that brings the mouth into direct contact with the genitals or rectum is the main route of pharyngeal gonorrhea. Condom use during fellatio greatly reduces but does not entirely eliminate risk, as contact between the tongue or lips and the genitals may still occur.
In most cases the source partner is unaware of carrying N. gonorrhoeae. It is common for a male partner to carry asymptomatic pharyngeal gonorrhea, or for a female partner to harbor asymptomatic endocervical infection. In Japan, the wide availability of commercial sex services that include oral sex contributes to a higher prevalence of pharyngeal gonorrhea and chlamydia than in many other countries.
Avoiding evaluation out of embarrassment is the worst possible decision: it allows unwitting transmission to partners and harms your own health. A men’s only clinic makes such consultations far less awkward.
The standard incubation period of pharyngeal gonorrhea is 2-7 days, similar to urethral gonorrhea. However, many cases remain asymptomatic for an extended period, and infection is often detected only incidentally on screening tests weeks to months after exposure. In symptomatic men, mild throat discomfort or pain typically begins within a few days of infection, then either resolves spontaneously, persists as a low-grade chronic syndrome, or recurs.
| Time after exposure | Status | Testing |
|---|---|---|
| 0-2 days | Incubation, bacterial replication | PCR positivity not yet reliable |
| 3-7 days | Symptoms appear in symptomatic cases; many asymptomatic | Detectable by gargle PCR |
| 1-4 weeks | Asymptomatic carriage in most; ongoing symptoms in a minority | High PCR sensitivity; culture also positive |
| 1-3 months | Chronic asymptomatic carriage; some spontaneous clearance | PCR remains positive in many |
| 3+ months | Long-term carriage, possible spontaneous clearance or symptom recurrence | Detected on periodic screening |
The optimal testing window is 3-7 days after the suspected exposure. Testing too early risks a false-negative result.
A subset of asymptomatic pharyngeal gonorrhea is cleared spontaneously by the immune system over weeks to months. Even so, waiting for natural clearance is not a viable strategy: partners are likely to be infected before clearance occurs, ongoing carriage may contribute to acquisition of resistance genes, rare cases progress to disseminated gonococcal infection (DGI: sepsis, arthritis), and concurrent chlamydia or syphilis may be missed. The medically and public-health-appropriate response is to begin appropriate antibiotic therapy immediately upon diagnosis.
Nucleic acid amplification testing (NAAT / PCR) is the modern gold standard for diagnosing pharyngeal gonorrhea. With sensitivity above 95% and specificity above 99%, it outperforms traditional culture. Results are available rapidly (same day to a few days), and the test reliably identifies infection regardless of symptoms. Sample types are gargle wash or pharyngeal swab. The gargle method requires the patient to gargle with normal saline (painless and gag-free), and is therefore widely adopted as a low-burden in-clinic technique.
| Method | Sensitivity | Specificity | Time to result | Patient burden |
|---|---|---|---|---|
| Gargle wash PCR | 95% or higher | 99% or higher | Same day to 3 days | Painless, self-collected |
| Pharyngeal swab PCR | 95% or higher | 99% or higher | Same day to 3 days | Mild gag reflex |
| Classical culture | 50-70% | 100% | 2-5 days | Gag reflex; lower sensitivity |
Combined PCR kits that detect both gonorrhea and chlamydia simultaneously are now standard, and Men’s Care Clinic routinely runs the combined panel.
It is a mistake to think I tested negative the day after a risky encounter, so I am fine. Always repeat testing after at least 1 week.
Because other STIs commonly co-occur with pharyngeal gonorrhea, simultaneous screening is recommended.
Men’s Care Clinic offers Throat Pack and Full Pack bundled testing, allowing comprehensive STI screening to be completed in a single visit.
The first-line treatment for pharyngeal gonorrhea is ceftriaxone (CTRX) 1 g as a single intramuscular injection or short intravenous infusion. This regimen is endorsed by the Japanese STI Guidelines 2020, the US CDC guidelines, and WHO recommendations, and is now the global standard. Previously favored oral cephalosporins (cefixime) and quinolones are no longer recommended for pharyngeal disease due to escalating resistance and treatment failures.
Ceftriaxone is a third-generation cephalosporin with potent bactericidal activity against gram-negative organisms. It is effective against pharyngeal, urethral, and rectal gonorrhea, and can be safely used in patients without penicillin allergy.
When chlamydia co-infection is suspected or confirmed, combination therapy with CTRX 1 g IM + azithromycin 1 g oral single dose is recommended. This clinically optimal regimen both raises the gonorrhea cure rate and simultaneously treats chlamydia. Gonorrhea treatment success is pushed above 98%, and the 20-40% of patients with asymptomatic chlamydia co-infection are treated in the same visit.
Recent years have seen increasing reports of N. gonorrhoeae strains with reduced susceptibility to ceftriaxone. In Japan, 10-20% of isolates show elevated CTRX MICs, and some patients fail to clear pharyngeal infection after first-line therapy. In suspected treatment failure, culture with antimicrobial susceptibility testing is performed, and individualized regimens such as combination therapy with gentamicin are considered.
Because pharyngeal gonorrhea has a higher treatment failure rate than urethral disease, a test of cure 2-4 weeks after treatment is mandatory. The pharyngeal mucosa receives lower antibiotic concentrations, so residual organisms are more likely. Sexual activity should be avoided until a negative test is documented; if positivity persists, a resistant strain must be considered and culture-based susceptibility testing pursued. Concurrent testing and treatment of partners is essential to prevent reinfection.
Because patients perceive little subjective discomfort, pharyngeal gonorrhea is frequently ignored, but leaving it untreated produces serious harms for both the patient and their partners. The thought I have no symptoms, maybe it will go away is a high-risk choice both individually and from a public-health standpoint, perpetuating transmission chains and accelerating antimicrobial resistance.
The elevation in HIV co-infection risk is particularly serious. Local inflammation caused by gonococci disrupts the mucosal barrier and facilitates HIV entry.
Unaware pharyngeal gonorrhea carriers who continue sexual activity will re-seed gonococcal infection in new and existing partners. Male partners may develop urethritis, prostatitis, or epididymitis; female partners may develop cervicitis, pelvic inflammatory disease (PID), tubal occlusion, infertility, or ectopic pregnancy. Transmission during pregnancy can cause neonatal gonococcal conjunctivitis (untreated blindness), preterm birth, and low birth weight, so consequences for a partner who becomes pregnant can be devastating.
The decision to avoid testing because of having no symptoms can therefore have irreversible effects on the future of a partner.
Long-term untreated pharyngeal gonorrhea creates a reservoir in which N. gonorrhoeae can exchange genetic material with resident bacteria and acquire resistance. The WHO has warned that ongoing antimicrobial resistance in gonorrhea threatens the emergence of an untreatable super-gonorrhea in the near future. A single treatment failure can propagate resistant strains across populations, so prompt treatment with confirmed cure is not only a personal but a societal responsibility. Individual early therapy contributes meaningfully to global AMR control.
Complete prevention of pharyngeal gonorrhea is difficult, but a combination of rational risk-reduction behaviors and partner testing substantially lowers the chance of infection. Avoid simplistic claims like condoms alone are enough; the realistic approach is to layer several prevention strategies.
Antiseptic gargles (for example povidone-iodine) have been studied as a way to reduce pharyngeal gonococcal carriage, but the preventive benefit is limited; condom use plus screening remains the most effective combination.
When pharyngeal gonorrhea is diagnosed, simultaneous testing and treatment of partners is standard practice. If only the index patient is treated, the partner’s residual asymptomatic infection will cause ping-pong reinfection immediately after therapy ends. All sexual partners from the past 2-3 months should be advised to test, and testing is mandatory even in asymptomatic partners. Sexual activity should not resume until the partner has completed treatment.
For monogamous couples, attending the clinic together is the most efficient approach. If you find it difficult to inform your partner, your physician can advise you, so please ask. Men’s Care Clinic also accommodates couples visits, so screening and treatment can proceed in a single, less awkward sequence.
Men’s Care Clinic is a men’s only medical facility that handles STIs, ED, AGA, and other male-specific concerns in a single integrated workflow. Beyond pharyngeal gonorrhea testing and treatment, we provide same-visit screening for pharyngeal chlamydia, syphilis, HIV, urethral gonorrhea, and other STIs; diagnosis to treatment can be completed in as little as one day. Our private rooms, predominantly male staff, and patient-flow design ensure you do not encounter other patients.
All clinics deliver the same standard of pharyngeal gonorrhea testing and treatment, and our partnership with Toyosu Hospital (Showa University system) ensures tertiary-hospital-level support for severe cases and complications.
Below, the physicians of Men’s Care Clinic answer (based on clinical experience) the questions most frequently asked in our STD clinic about pharyngeal gonorrhea.
A. A small proportion of asymptomatic carriers may clear the infection over a few months, but many remain colonized long-term. While awaiting natural clearance, partners may be infected and antimicrobial resistance can evolve, so once a diagnosis is made the medically and public-health-appropriate course is prompt antibiotic therapy.
A. If you have had oral sex and your symptoms persist longer than 2 weeks or do not improve with antibiotics, pharyngeal gonorrhea must be considered. When persistent throat discomfort fails to respond to ordinary cold medicine, get a PCR test at an STD clinic.
A. STD clinics, infectious-disease services, and urology are the first-choice settings. For integrated care of male-specific co-infections (urethral gonorrhea, prostatitis, ED), a men’s only clinic is ideal; testing and treatment can be completed in as little as one day.
A. Symptoms alone cannot reliably distinguish the two. Definitive diagnosis requires gargle PCR. If you have a sexual contact history and symptoms persist over 2 weeks or fail to respond to antibiotics, undergo PCR testing at an STD clinic.
A. Including the first-visit fee, PCR testing, and ceftriaxone 1 g IM, expect JPY 15,000-30,000 out-of-pocket as a general guide. With simultaneous chlamydia testing and treatment, the total is roughly JPY 25,000-40,000. STIs are generally treated under self-pay (non-insurance) care in Japan.
A. Wait at least 1 week, and ideally resume only after a negative test of cure (2-4 weeks post-treatment). Because pharyngeal gonorrhea has a higher treatment failure rate, a confirmed negative PCR is essential.
A. Yes, it is mandatory. Asymptomatic carriage of the pharynx, urethra, or endocervix is common, so without partner testing and treatment, ping-pong reinfection is almost guaranteed. Simultaneous couple testing and treatment is standard.
A. Oral sex is the main route, but deep kissing can also transmit infection if both parties have pharyngeal carriage. Ordinary kissing or shared utensils essentially do not transmit the infection.
A. Modern guidelines do not recommend oral therapy. Oral cephalosporins and quinolones have substantial resistance and poor pharyngeal drug penetration, so single-dose intramuscular ceftriaxone 1 g is the first-line therapy.
A. Some research suggests antiseptic gargles modestly reduce pharyngeal gonococcal carriage, but the preventive effect is limited. Condom use combined with routine screening is the most effective approach.
A. Yes. The WHO reports that pharyngeal gonorrhea elevates HIV transmission risk 2-3 fold because mucosal inflammation disrupts the protective barrier. Treating pharyngeal gonorrhea therefore also contributes to HIV prevention.
A. The first visit requires in-person testing and injection; ceftriaxone 1 g IM cannot be administered remotely. However, follow-up visits such as test of cure or partner counseling can sometimes be completed by online consultation.
A. Yes, repeatedly. Gonococcal infection does not produce protective immunity, so reinfection from new sexual contacts is straightforward. If you are sexually active, schedule routine screening every 3-6 months.
A. Possible treatment failure or a resistant strain. Return to your clinic promptly for repeat PCR and culture with antimicrobial susceptibility testing. Resistant strains may require individualized therapy such as gentamicin combination.
A. The gonococcus itself does not cause ED, but post-diagnosis anxiety and tension with a partner can trigger psychogenic ED. Men’s Care Clinic operates a combined STI and ED service, allowing integrated management.
Pharyngeal gonorrhea (gonococcal infection of the throat) is a major STI in which 80-90% of men remain asymptomatic, a true silent infection, and untreated cases cause significant individual, partner, and public-health harms. The good news: with appropriate testing (gargle PCR) and treatment (ceftriaxone 1 g single-dose IM), cure rates exceed 95%.
Key takeaways from this article:
At Men’s Care Clinic, our men’s only physicians provide inspection, gargle PCR, and same-day ceftriaxone 1 g IM in a single integrated workflow. Please also see our articles on pharyngeal chlamydia and male STIs overview.
If you suspect that you might have pharyngeal gonorrhea, that your throat feels strange after using commercial sex services, or that your partner has been diagnosed with an STI, please consult our STD clinic counseling service first. Early evaluation and early treatment will keep pharyngeal gonorrhea firmly under control.
STD
関連記事
2026/04/16 STD 【医師監修】クラミジアとは？男性の症状・感染経路・検査・治療を徹底解説
2026/04/04 STD 【医師監修】男性の梅毒とは？症状・感染経路・検査・治療を徹底解説
2022/11/07 STD 梅毒の進行ステージと放置リスク｜第1期〜第4期の症状を医師が徹底解説【2026年最新】
2021/09/19 STD 尖圭コンジローマ｜男性の症状・治療・HPVワクチンを医師が徹底解説【2026年最新】
2021/09/19 STD B型肝炎の治療と放置リスク｜HBs抗原・HBVワクチン・核酸アナログ療法を医師が徹底解説【2026年最新】
2021/09/19 STD C型肝炎の治療と放置リスク｜DAA療法でSVR95%超を目指す最新治療を医師が解説【2026年最新】
2021/09/19 STD 男性のトリコモナス｜無症状でもうつる？放置リスクと検査・治療法
2021/05/08 STD マイコプラズマ感染症（男性）｜症状・検査・治療・耐性菌対策まで医師監修で徹底解説
2021/05/05 STD 男性のヘルペス｜性器・口唇の症状・治療・再発予防を医師が徹底解説【2026年最新】
2021/05/02 STD 男性の性器カンジダ症｜亀頭炎・包皮炎の症状・治療・予防を医師が徹底解説【2026年最新】
2026.04.16
STD
【医師監修】クラミジアとは？男性の症状・感染経路・検査・治療を徹底解説
2026.04.04
STD
【医師監修】男性の梅毒とは？症状・感染経路・検査・治療を徹底解説
2022.11.07
STD
梅毒の進行ステージと放置リスク｜第1期〜第4期の症状を医師が徹底解説【2026年最新】
2021.09.19
STD
尖圭コンジローマ｜男性の症状・治療・HPVワクチンを医師が徹底解説【2026年最新】
2021.09.19
STD
B型肝炎の治療と放置リスク｜HBs抗原・HBVワクチン・核酸アナログ療法を医師が徹底解説【2026年最新】
2021.09.19
STD
C型肝炎の治療と放置リスク｜DAA療法でSVR95%超を目指す最新治療を医師が解説【2026年最新】
2021.09.19
STD
男性のトリコモナス｜無症状でもうつる？放置リスクと検査・治療法
2021.05.08
STD
マイコプラズマ感染症（男性）｜症状・検査・治療・耐性菌対策まで医師監修で徹底解説
2021.05.05
STD
男性のヘルペス｜性器・口唇の症状・治療・再発予防を医師が徹底解説【2026年最新】
2021.05.02
STD
男性の性器カンジダ症｜亀頭炎・包皮炎の症状・治療・予防を医師が徹底解説【2026年最新】
AGA